Targeting the Microglia Brain Immune system with TREM2 Agonism as a Broad Therapy for Alzheimer’s Disease
Time: 11:00 am
day: Clinical & Commercial Track Day 2 AM
Details:
- Trem2 is a damage sensing microglia receptor. Partial loss of TREM2 increases AD risk while high levels appear protective
- AL002, Alector Trem2 activating biologics was shown to be well tolerated, engage microglia and is associated with incidences of ARIA-like events in AD
- Clinical, imaging, and biomarkers data from a double-blind, placebo-controlled, 4-dose arm, Phase 2 study in early AD patients is expected in Q4 2024
